On February 6, 2018 TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, reported that its President and CEO, Peter Hoang, will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City (Press release, TapImmune, FEB 6, 2018, View Source [SID1234523778]). He will also attend the 11th Annual European Life Sciences CEO Forum & Exhibition, held February 26-27, 2018, in Zurich, Switzerland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TapImmune Presentation Details:

Event: 2018 BIO CEO & Investor Conference

Date: Monday, February 12, 2018

Time: 2:30 PM (Eastern Time)

Location: New York Marriott Marquis, Odets Room

An audio webcast will be accessible via the News and Events section of the TapImmune website: View Source An archive of the audio will remain available for 90 days following the presentation.